The document discusses the concept of a "biotech social contract" where the biotech industry commits to developing new medicines and technologies that will eventually become generic, and society commits to providing universal health insurance with low out-of-pocket costs so patients can afford treatments. It encourages writing an op-ed framing drug development within this social contract and calling on legislators to eliminate out-of-pocket costs to uphold society's end of the bargain and ensure patients can access needed treatments.